首页> Scientific reports> Dose-dependent impact of tixagevimab-cilgavimab as primary prevention against SARS-CoV-2 in immunocompromised individuals.

Dose-dependent impact of tixagevimab-cilgavimab as primary prevention against SARS-CoV-2 in immunocompromised individuals.

导出 LinkOut

翻译打印收藏纠错

第一作者： Daniela,Dluzynski

第一单位： Penn State College of Medicine, Hershey, PA, USA.

作者： Daniela,Dluzynski ^[1] ; Paddy,Ssentongo ^[2] ; Cory M,Hale ^[3] ; Shareef K,Shaheen ^[1] ; Natella,Maglakelidze ^[1] ; Jeffrey M,Sivik ^[3] ; Maria Paula,Henao ^[4] ; Vernon M,Chinchilli ^[5] ; Catharine I,Paules ^[6]

作者单位： Penn State College of Medicine, Hershey, PA, USA. ^[1] Division of Infectious Diseases, Department of Medicine, Penn State Health Milton S. Hershey Medical Center, 500 University Drive, Room #C6860, MCH036, Hershey, PA, 17033, USA. ^[2] Department of Pharmacy, Penn State Health Milton S. Hershey Medical Center, Hershey, PA, USA. ^[3] Division of Allergy and Immunology, Department of Medicine, Penn State Health Milton S. Hershey Medical Center, Hershey, PA, USA. ^[4] Department of Public Health Sciences, Penn State College of Medicine, Hershey, PA, USA. ^[5] Division of Infectious Diseases, Department of Medicine, Penn State Health Milton S. Hershey Medical Center, 500 University Drive, Room #C6860, MCH036, Hershey, PA, 17033, USA. cpaules@pennstatehealth.psu.edu. ^[6]

关键词 COVID-19 Chimeric antigen receptor (CAR)-T cell therapy Hematopoietic stem cell transplant Monoclonal antibody Tixagevimab–cilgavimab